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Many cancer patients are anxious even when disease is in remission. Anxiety about health, ‘health anxiety’, has distinct features,
notably seeking medical reassurance about symptoms. Doctors may then communicate that these symptoms are not due to serious
illness, a process known as ‘reassurance’. However, reassurance may inadvertently perpetuate some patients’ anxiety. We aimed to
observe the relation between symptoms, anxiety and reassurance in consultations with cancer patients. A total of 95 outpatients, with
breast or testicular cancers in remission, completed questionnaires measuring health anxiety at study entry, then general anxiety –
before a consultation, immediately afterwards, 1 week later, and before their next consultation. We examined symptoms reported
and reassurance by oncologists from audio recordings of consultations, and the outcome of subjects’ anxiety. The results showed that
substantial health anxiety was reported by one-third of the patients. Patients with higher levels of health anxiety reported more
symptoms during consultations. Reassurance was ubiquitous, but not followed by an enduring improvement in anxiety. Certain forms
of reassurance predicted increased anxiety over time, particularly for subjects who were most anxious. In conclusion, health anxiety
can be a problem after cancer. Reassurance may not reduce patients’ anxiety. Some reassurance was counterproductive for the most
anxious patients. Oncologists may need to use reassurance as a procedure, balancing risk, and benefits, and patient selection and to
manage cancer patients in remission.
British Journal of Cancer (2004) 91, 893–899. doi:10.1038/sj.bjc.6602077 www.bjcancer.com
Published online 3 August 2004
& 2004 Cancer Research UK
Keywords: anxiety; reassurance; remission; health anxiety
                                                 
We have previously demonstrated that many cancer patients are
highly anxious (Stark et al, 2002). After treatment the prevalence of
morbid anxiety falls, but may not return to baseline (Noyes et al,
1998). There is an incomplete understanding of who remains
anxious, and what oncologists can do in consultations to improve
this. There may be features of anxiety about health described in
settings outside cancer care, which may be observed in cancer
patients, and which we can ‘translate’ to improve the management
of the anxious cancer patient.
Anxiety about health may be associated with a spectrum of
symptoms, such as nausea and fatigue, but a characteristic pattern
of beliefs, concerns and behaviours has also been described, which
is distinct from general anxiety (Forester et al, 1993; Lucock and
Morley, 1996; Cameron et al, 1998). The main features of so-called
‘health anxiety’ are:
  Beliefs
A tendency to interpret everyday bodily symptoms as
indicating serious disease
  Concerns
Intrusive worrying and preoccupation with health, to the
detriment of other activities
Fear of serious illness, such that news or events concerning
illness in other people causes fear in the patient
  Behaviours
Reassurance-seeking: seeking medical consultations, asking
friends and family about bodily symptoms, or reading about
illnesses (Lucock and Morley, 1996).
As cancer patients remain anxious about their health, we aim to
examine whether these features are reported by patients and
observed in consultations after cancer treatment (see hypothesis 1).
Surveillance is widely practiced after cancer treatment, to detect
relapse and to assist patients’ psychological adaptation (Working
group on socio-psychological implications of follow-up, 1995). This
may increase as treatment improves, and early detection expands.
During clinical surveillance, patients may enquire about their
symptoms. Oncologists may then seek to explain that the symptoms
experienced are not due to worsening of the cancer. The process of
explanation that symptoms are not due to serious disease is
commonly referred to as ‘reassurance’, and has been widely studied
within medical care outside oncology (McDonald et al, 1996;
Howard and Wessely, 1996; Kathol, 1997; Lucock et al, 1997; Coia
and Morley, 1998; Starcevic, 2001). Reassurance takes various
forms, but frequently includes simple statements such as ‘not to
worry’ about serious disease being present, explanation about the
symptom, and radiological or other investigation (Howard and
Wessely, 1996; Kathol, 1997; Coia and Morley, 1998; Price, 2000).
We therefore aim to examine the frequency and types reassurance
used in oncological consultations (see hypothesis 2).
When patients present with nonspecific symptoms, reassurance
initially reduces general anxiety (Lucock et al, 1997; Conroy et al,
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has been successful. The presence of health anxiety defines
a group whose general anxiety rapidly returns, which the
clinician may be less aware of (Coia and Morley, 1998). Over a
longer time, well-meaning reassurance may actually maintain
general anxiety. An analogy exists with phobias, where avoiding
the stimulus serves to reduce short-term anxiety, but maintains the
phobia in the long term (Salkovskis and Warwick, 2001). We aim
to examine whether this model is supported by the pattern
of general anxiety after consultations with cancer patients
(see hypothesis 3).
Health anxiety has been described in the medically well
population, but after cancer the features may differ. Patients
monitor their bodies for symptoms of relapse, and interpret any
symptoms in that light. Therefore, cancer patients might be
expected to report health anxiety as a transient phenomenon after
diagnosis. Features of health anxiety, such as seeking advice about
symptoms, are not necessarily unsuccessful in reducing anxiety
after a major illness. Reassurance-seeking is only maladaptive if it
becomes an enduring and cyclical coping pattern (Salkovskis and
Warwick, 2001). Such a process might be observed during
consultations for cancer patients in remission; patients report
symptoms, medical reassurance follows, then a transient fall in
anxiety. Anxiety rapidly returns, sometimes increased, followed by
further reporting of symptoms at later consultations, perpetuating
the problem. This may inform us (1) why some patients remain
anxious, (2) identify a group of patients for whom reassurance is
not useful and (3) indicate the potential for techniques used
managing health anxiety to ‘translate’ into improved psychological
outcomes.
These issues have a substantial impact upon oncology practice,
affecting patient’s well being and medical workload. We therefore
aim to examine, in particular, several hypotheses:
(1) Health anxiety will be present in cancer patients in remission
(a) Health anxiety will reported by cancer patients in
remission.
(b)Health anxiety will predict behaviour during consultations
– repeated reassurance-seeking, taking the form of enqui-
ries about symptoms, during consultations.
(2) A range of forms of reassurance will be observed in medical
consultations for cancer patients in remission.
(3) The pattern of anxiety after reassurance will be as predicted by
observations about health anxiety in other settings.
(a) Reassurance will reduce general anxiety, but only transi-
ently.
(b)Following a transient fall, general anxiety will increase after
reassurance, particularly in subjects with high levels of
health anxiety.
METHODS
Cohort and setting
This longitudinal observational cohort study recruited consecutive
patients under outpatient review in breast or testicular tumour
clinics in Leeds, UK. Eligible patients were in clinical complete
remission, within 2 years of diagnosis, and undergoing follow-up
at intervals of o4 months. The only exclusion criterion was
inadequate literacy in English. After recruitment if there was
clinical doubt that the cancer remained in remission, all data on
that subject were excluded from analysis. Patients were ap-
proached prior to a medical consultation, the study discussed
and written information given, but written consent was sought at
their next appointment.
Definitions
In this report, ‘health anxiety’ refers to the specific pattern of
beliefs, concerns and behaviours described. ‘General anxiety’
describes a broader problem, characterised by somatic symptoms
of autonomic overactivity at the immediate time of measurement.
‘Reassurance’ refers to statements communicating to patients that
the symptoms are not due to serious disease, in this case that
cancer is not active (Howard and Wessely, 1996; McDonald et al,
1996; Kathol, 1997; Lucock et al, 1997; Coia and Morley, 1998;
Starcevic, 2001).
Questionnaires and measures
The State Trait Anxiety Inventory (STAI) The 20-item STAI-S
(‘state’) questionnaire measures general anxiety at the time of
completion. Items have four response categories from ‘not at all’ to
‘very much so’, giving scores from 20 to 80. In previous studies of
cancer patients with anxiety disorders by standardised psychiatric
criteria, mean STAI-S was 44.4, in contrast to 36 in those with
normal levels of anxiety (Stark et al, 2002). The measure has been
used for 30 years, with cancer patients, and has demonstrated
factor structure and sensitivity to change (Spielberger, 1983;
Fogarty et al, 1999).
The Health Anxiety Questionnaire (HAQ) The HAQ is a 21-item
questionnaire measuring beliefs, concerns and behaviours asso-
ciated with health anxiety. Four response categories assess the
frequency of problems over one preceding week, from ‘not at all or
rarely’ to ‘most of the time’, scored 0–3. In an initial validation
study of medical outpatients with unexplained symptoms, mean
score was 17.4. In a lay group, the mean score was 8.6, for
psychology outpatients with anxiety problems 23, and a hypo-
chondriacal population 35 (Lucock and Morley, 1996).
We altered some items for cancer patients. Some ‘worrying about
health’ is normal after cancer, so we substituted ‘how ofteny’i n
place of the original ‘do youy.’. An item referring to fear of having
cancer was omitted. A question was added about interference due
to worry; ‘how much has worry about your illness interfered with
work, concentration or enjoyment during the last 6 months’.
Communication during the medical consultation
The Medical Interaction Process System (MIPS) is an ‘utterance’-
based analysis of verbal communication. Utterances are clauses of
a sentence, ranging from single words to lengthy phrases, each of
which carries a separate item of information. Each utterance is
coded by the manner in which the information is exchanged, such
as ‘asks open question’, or ‘interrupts’. The majority of utterances
will also have a content, such as ‘related to the cancer, tests, side
effects of treatment’ or ‘life-style’. These are determined by the
syntax and by its context. The MIPS was derived in oncology (Ford
et al, 2000), and has good to excellent inter-rater and rate-rerate
reliability (Fallowfield et al, 2002). We devised and formalised
adaptations to the MIPS to classify reassurance, after training from
the group who developed MIPS:
Reassurance-seeking was defined as the patient reporting a
physical symptom (Salkovskis and Warwick, 2001).
Medical reassurance was classified (Howard and Wessely, 1996;
Kathol, 1997; Price, 2000; Starcevic, 2001):
  Either in response to a symptom raised by the patient
* Simple reassurance, such as ‘this is not due to serious disease’
‘that’s ok’ ‘don’t worry’.
* Education. Information is given with simple assurances, for
example, ‘that’s due to y.’, ‘the symptom is because of y’.
* A plan, For example, ‘I will take a look at that’, ‘we will do
some tests’. This did not include ambivalent statements such
as ‘if you have problems call us’.
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* Initiated by the doctor, not in response to a prior patients
concern. Statements such as ‘you look well’, or ‘things are
going well’.
DS and MK were trained by the group who developed the MIPS.
DS performed the ratings, using a coding sheet developed
alongside the MIPS (Ford et al, 2000). A random sample of 10%
of interviews was selected, and rerated by DS and MK, to assess
reliability (Bland and Altman, 1996).
The schedule of measures is outlined in Figure 1. Case note
review yielded age, gender and time since cancer diagnosis.
Education (schooling and since school) was measured by patient
report. Socioeconomic group was estimated from postcode (Stark
et al, 2002).
Statistical considerations
Analyses were performed with SPSS version 9. Correlations and
general linear models were applied after appropriate simple
transformations. Sample size was planned to permit stable
multivariate analyses including potential confounding variables
and planned interaction analyses. This required 10 subjects
per variable, a target sample size of 90 (Altman, 1996). All vari-
ables were subject to analyses, as all were of interest a priori,
using a general linear model. Outlying subjects were excluded from
general linear models if standardised residual values were 43.3
(Tabachnick and Fidell, 1996).
The HAQ scores were skewed, so were categorised into tertiles.
Previously this has delineated groups with distinct responses to
reassurance (Lucock et al, 1997). All MIPS ratings were performed
blind to other variables. Intraclass correlation coefficient was used
to examine reliability of the adapted MIPS ratings, using a two-way
mixed effects model (Nichols, 1998).
RESULTS
The Cohort, consent, missing data and attrition
A total of 160 consecutive eligible patients were offered study
entry. Of these, 130 (81%) gave informed consent. A further 35
subjects gave incomplete data at 1 or more time points, due to
uncertainty about relapse or patient preference. Total of 95
subjects gave data at all points. The group who gave incomplete
data were more likely to have breast cancer (w
2¼5.91, P¼0.05),
but similar by age and socioeconomic group (unpaired t tests
P40.25).
Description of the main variables (Table 1) A total of 62 subjects
(65%) had testicular cancer. In all, 34% of the subjects had
completed only basic school education, 41% higher education and
the remaining 25% further education after age 18 years.
Health anxiety by the HAQ had good internal consistency
(Cronbachs a¼0.93) but scores were positively skewed. The
highest one-third by the health anxiety score had a mean score of
24.6, reflecting health anxiety similar to psychology outpatients,
and the remaining two-third had a mean score of 6.6, in keeping
with a normal population. Health anxiety levels were not related to
time since cancer diagnosis (Table 1).
Reliability of the MIPS was good. Intraclass correlation
coefficients, between raters and rate-rerate, ranged from 0.69 to
0.93.
All the consultations analysed were with qualified medical staff.
A total of 39 doctors contributed, but six carried out five or more
consultations. The commonest symptoms reported by patients
were pains, mentioned in 430 consultations. Of the 190
consultations, 97% included some form of reassurance. Simple
reassurance was used in 72%, educational reassurance in 60%, plan
in 38% and spontaneous reassurance in 49%. Their frequencies are
given in Table 1. There was a mean of 85 utterances per
consultation (range 45–717), of which reassurance constituted a
mean of 7.6%.
Relation between the main variables (Table 1) The subjects with
testicular tumour were younger than those with breast cancer
(mean 36.8 vs 61.9, unpaired t¼11.2, Po0.001). The range of ages
was wide – 16.7–72.5 for the testicular group and 44.0–77.1 for the
breast cancer group. Education was very different between the two
cancers; 67% of the women with breast cancer had completed basic
education only, in contrast to 16% of the men with testicular
cancer. There was no statistically significant difference between the
two cancer types by socioeconomic status, or time since diagnosis
(Mann–Whitney U, P40.1).
The mean general anxiety at baseline was 33.7 for men and 38.9
for women (unpaired t¼2.2, P¼0.03). General anxiety and health
anxiety are correlated, but not very strongly, suggesting they are
related but distinct.
Consultation 1
audio-taped
and analysed
by MIPS
Measurement 1
Questionnaires
immediately
before first
consultation:
STAI-S HAQ  
Baseline social,
demographic
and
oncological
data  
Measurement 2
Questionnaires
immediately
after first
consultation:
STAI-S 
Measurement 3
Questionnaires
1 week
after first
consultation:
STAI-S
Measurement 4
Questionnaires
immediately
before second
consultation:
STAI-S
Consultation 2
audio-taped
and analysed
by MIPS
Figure 1 The sequence of measures.
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doctors in training) was 40 and 21% in subjects with breast and
testicular cancer, respectively (w
2 3.52, 2 sided P¼0.07). Women
reported more symptoms (median 5/consultation) than men (3/
consultation, Mann–Whitney U test P¼0.01). The number of
reassurance utterances of each type per consultation was not
statistically significantly different, when the two cancer types were
compared (T tests, P40.05). The 6 doctors who carried out more
than 5 consultations were not statistically significantly different in
the frequencies of types of reassurance used (Kruskal-Wallis
P40.15). Spontaneous reassurance was not more frequent when
the patient had high general anxiety (Table 1).
Health anxiety and anxiety over time
General anxiety measured by the STAI-S fell after the first
consultation, but returned to baseline before the second consulta-
tion (Figure 2).
The statistically significant predictors of the within-patient
change in general anxiety, comparing measurement 1 to measure-
ment 4 with a general linear model, were:- health anxiety,
B¼ 0.67 (95% confidence interval  1.2 to  0.13, f(1,91) 3.95,
P¼0.02), and the interaction; health anxiety*general anxiety at
baseline B¼0.01 (95% confidence interval 0.00–0.02) P¼0.05).
General anxiety at baseline was not an independent predictor
(B¼0.19 (95% confidence interval –0.1–0.47), P¼0.18). Inde-
pendent of the initial level of general anxiety, higher health anxiety
predicted a poorer outcome for general anxiety (Table 2).
Health anxiety and symptoms
The two-thirds of the cohort with least health anxiety reported a
mean of 1.3 symptoms/consultation, while the one-third with most
health anxiety reported a mean of 2.3/consultation. Health anxiety
predicted the number of symptoms reported at consultation 1
(univariate B¼0.01 in predicting the logarithm of number of
symptoms raised, f(1,93) 7.72, P¼0.01). This remains of border-
line significance (multivariate B¼0.01, f(1,88) 3.77, P¼0.06) when
controlled for cancer type, age, education and general anxiety.
Health anxiety strongly independently predicts the number of
symptoms reported at consultation 2, indicating that this is a
consistent behaviour (Table 3).
Medical reassurance and the outcome of anxiety
The immediate fall in general anxiety seen after the first
consultation was not related to the type or amount of reassurance
observed (all P40.20, univariate or multivariate analyses, data not
shown). By measurement 3, 1 week later, the use of a plan as
reassurance was associated with increasing anxiety by multivariate
analysis (f(1,87) 7.69, B¼ 1.47, P¼0.01).
Table 1 Spearmans’ rank correlations between major sociodemographic, oncological, psychological and communication variables at consultation 1
Descriptive data Spearmans rank correlations
Mean, range,
s.d.
Years since
diagnosis
Full-time
education Anxiety
Number of
reassurance-
seeking
behaviors Number of medical reassurance utterances
Health
anxiety STAI-S Simple Education Plan Spontaneous
Age 45.5, 17–77, 15.9 0.09  0.57** 0.17 0.17 0.24* 0.22* 0.10  0.01  0.09
Years since
diagnosis
1.29, 0.2–2.3, 0.5  0.14  0.07  0.003  0.05  0.00  0.10  0.06  0.14
Full-time education
(years)
12.7, 9–19, 3.1  0.09  0.14  0.22*  0.19  0.05  0.09  0.02
Health anxiety
(HAQ)
12.8, 0–54, 10.6 0.52** 0.24* 0.23* 0.15 0.11  0.18
General anxiety
(STAI-S)
35.5, 20–78, 11.5 0.28** 0.31** 0.29** 0.13  0.13
Reassurance-seeking
behaviors
1.6, 0–13, 2.1 0.61** 0.59** 0.51**  0.46**
Reassurance: simple 2.4, 0–11, 2.5 0.60** 0.33**  0.53**
Educational 2.3, 0–23, 3.5 0.37**  0.47**
Plan 0.9, 0–6, 1.4  0.17
Spontaneous 1.2, 0–11, 1.8
In bold, in the first column, are simple descriptive data; mean, range, standard deviation; STAI-S¼State Trait Anxiety Inventory (state). N¼95. s.d.¼standard deviation;
**Correlation is significant at the 0.01 level; *significant at the 0.05 level (two-tailed).
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Figure 2 The levels of general anxiety at the 4 time points: – before the
first consultation, immediately after, 1 week later and before the following
consultation. N¼95.
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assessment (Figure 1) spontaneous reassurance predicted an
increase in general anxiety in univariate analysis (B¼ 1.13,
95% confidence interval –2.19 to –0.07, P¼0.04). On multivariate
analyses, spontaneous reassurance did not remain an independent
predictor of the change in anxiety (f(1,91) 2.46, B¼ 0.78,
P¼0.12). The change in general anxiety by the following
appointment was not predicted by an interaction between
health anxiety and spontaneous reassurance either. The associa-
tion between spontaneous reassurance and a later increase
in general anxiety was therefore not a function of the health
anxiety level.
We examined how spontaneous reassurance (during the first
consultation, measured by the MIPS) was related to the within-
patient changes in general anxiety at different baseline levels of
general anxiety. At low baseline levels of general anxiety, the
amount of spontaneous reassurance had little relation to the
change in general anxiety by the fourth point of assessment, prior
to the second consultation. At higher levels of general anxiety, less
use of spontaneous reassurance was associated with a fall in
general anxiety, a regression to the mean. However, more
spontaneous reassurance was followed by a rise in general anxiety,
in the subjects who were already the most anxious (Tables 4
and 5). This suggests that for individuals with high levels of
general anxiety, spontaneous medical reassurance may be counter-
productive.
DISCUSSION
Health anxiety appears common in cancer patients in remission.
About one-third of subjects reported beliefs, concerns and
behaviours typical of health anxiety, and comparable to patients
receiving psychological treatment. Health anxiety levels are not
related to time since cancer diagnosis, suggesting that they are not
simply an adaptive phase. The mean level of general anxiety in the
population studied was not high for a cancer patient population;
one-third had levels of general anxiety likely to be clinically
significant.
Despite the problems in examining such behaviours after a
cancer diagnosis, we observed several features of the consultation
that are typical of those found in health anxiety. We found high
levels of reporting of symptoms in consultations with cancer
patients in remission. Over two consecutive consultations, health
anxiety predicted more symptom reporting, which is identified in
the descriptions of health anxiety as a frequent reassurance-
seeking behaviour (Lucock and Morley, 1996).
Reassurance that symptoms are not sinister seemed ubiquitous.
Anxiety fell after consultation whatever forms of reassurance were
observed, but only transiently. In cancer care as elsewhere in
medicine, reassurances that the disease is not present may not
result in enduring reductions in anxiety (McDonald et al, 1996).
After 1 week of follow-up, and longer, different forms of
reassurance did not have the same impact. As hypothesised,
increased anxiety over time followed some forms of reassurance.
Table 3 A multivariate linear regression model predicting the (logarithm
of the) number of symptoms raised at the second recorded consultation,
from health anxiety at measurement 1, oncological and demographic
variables, and general anxiety at measurement 4
95% confidence
interval
Variable Category B Lower Upper P
Cancer type (compared
to breast cancer)
Testicular cancer  0.05  0.25 0.16 0.65
Age 0.00  0.01 0.00 0.34
School education,
comparing to basic
education
Higher  0.27  0.48  0.06 0.01
Further  0.24  .041  0.07 0.01
Overall 0.02
General anxiety at
measurement point 4
 0.00  0.01 0.00 0.65
Health Anxiety at
measurement point 1
0.01 0.00 0.02 0.01
N¼95. Adjusted R
2¼0.13.
Table 4 Association between the use of spontaneous reassurance, the
level of general anxiety at measurement 1 (by STAI-S), and the within-
patient change in general anxiety, comparing measurement 1 to
measurment 4
95% confidence
interval
Variable B Lower Higher P
Baseline general anxiety 0.41 0.22 0.61 0.00
Time (years) since cancer diagnosis 2.72  0.59 6.02 0.11
Number of spontaneous reassurance
behaviours
3.34  0.65 7.33 0.10
Interaction between baseline general
anxiety and number of spontaneous
reassurance behaviours
 0.12  0.24  0.008 0.04
N¼95. Note: The analysis is by a general linear model. This aims to predict the
change in general anxiety over time, comparing measurement 1 to measurement 4.
Adjusted R
2¼0.20.
Table 5 Interaction between general anxiety at measurement 1
(measured by STAI-S), and the number of spontaneous reassurance
utterances (measured by MIPS during consultation 1), in predicting the
change in general anxiety comparing measurement 1 to measurement 4
Baseline general
anxiety
Number of
spontaneous
reassurance utterances
Increase in general
anxiety
Lower (25) Lower (0) 4.95
Lower (25) Higher (3) 3.93
Higher (46.5) Lower (0)  3.87 (a fall)
Higher (46.5) Higher (3) 2.86
Note: The values for general anxiety (STAI-S, State Trait Anxiety Inventory (state))
and number of spontaneous reassurance utterances (MIPS, Medical Interaction
Process System) are the mean observed values for the lowest two-thirds and the
highest one-third of the study distribution, respectively. The change in STAI-S is
calculated from the general linear model described in the text.
Table 2 Illustration of the interaction between health anxiety and
general anxiety at measurement 1 in predicting the change in general
anxiety from measurement 1 to measurement 4
HAQ STAI-S Fall in STAI-S
Lower (6) Lower (25) 2.2
Higher (24) Lower (25)  5.3 (a rise)
Lower (6) Higher (46.5) 7.6
Higher (24) Higher (46.5) 3.9
Note: The values for health anxiety (HAQ, Health Anxiety Questionnaire) and
general anxiety (STAI-S, State Trait Anxiety Inventory (state)) are the mean observed
values for the lowest two-thirds and the highest one-third of the study distribution,
respectively. The change in STAI-S is calculated from the general linear model
described in the text.
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outcome for anxiety if it allows avoidance of the focus of anxiety
(Salkovskis and Warwick, 2001). Spontaneous reassurance, re-
assurance offered before the patients raised their own concerns,
appeared to be followed by a worse outcome for the most anxious.
This could have been because the doctors were using spontaneous
reassurance when they perceived the patients as anxious, but there
was little relation between the use of this form of reassurance
and general anxiety levels (Table 1). Another alternative inter-
pretation of the results would be that a higher level of symptoms
results in health anxiety, and reassurance-seeking. While this
cannot be entirely refuted in an observational study, it is not
supported by data in other settings, which suggest it the
interpretation by the patient, not the presence of symptoms,
which is the basis of health anxiety (Coia and Morley, 1998;
Salkovskis and Warwick, 2001).
We observed differences, as well as some similarities, between
health anxiety in this setting and when there is no diagnosis of
serious disease (Coia and Morley, 1998). Notably, a poor outcome
after reassurance was not specific to subjects with high levels of
health anxiety, and may be more closely related to high levels of
general anxiety.
Limitations of the study
Several aspects of the study design should be considered. The
cohort included cancers that differed in gender, age, education and
characteristics of the consultation. Interaction analyses have been
performed for the main findings. None indicate statistically
significant heterogeneity of the results by cancer type (data not
shown). This design cannot examine gender and cancer type
separately, which merits further study. The rate of consent was
high although the rate of attrition was disappointing, but we were
required to be rigorous in excluding patients when progression of
the cancer was considered in doubt.
Several of the measures used were adapted for this study. This
had little effect upon the quality of these measures, as the
distribution, reliability and correlation analyses observed are very
similar to those observed using the original HAQ in other medical
outpatient groups (Lucock and Morley, 1996; Lucock et al, 1997).
The MIPS was also altered, providing further detail of reassurance
utterances that were previously grouped (Ford et al, 2000). These
patient populations were selected for study because locally they
undergo protocol-based surveillance when in remission. These
results are likely to generalise to other patients undergoing similar
surveillance, although this merits further study.
The timing of the measures is such that some of the general
anxiety observed may be anticipatory, related to the impending
appointment. Worry about illness and a belief that illness is
present have previously been demonstrated to return despite
reassurance, and continue in measurements taken at home over 12
months (Lucock et al, 1997). Therefore, the patterns of fall and rise
in general anxiety observed for anxious subjects are likely to reflect
the patients’ experiences between appointments.This study does
not include the measurement of other psychological variables,
such as personality, trait anxiety or depression. Further explora-
tion of the interplay of these variables with communication within
the consultation would be interesting, as they are closely related to
health anxiety (Salkovskis and Warwick, 2001). However, health
anxiety has previously been demonstrated to distinguish indivi-
duals with resistance to medical reassurance, independent of levels
of depression or of a personality that tends to anxiety (Lucock and
Morley, 1996).
Implications for future research
There are several questions raised that could be examined in
future. The pattern of symptoms, beliefs, concerns and behaviours
described may help to explain why some cancer patients remain
anxious. This is an observational study, and therefore causal
relationships should not be inferred from this study alone. The
findings do suggest that all reassurance is not the same, but also
that reassurance should be considered a specific intervention, with
potential benefits, but risks for some groups of patients. It has also
been suggested that reassurance should be carefully timed, and
particularly that an awareness of a patient’s specific concerns is
helpful in providing effective reassurance (Donovan and Blake,
2000; Price, 2000; Starcevic, 2001). Spontaneous reassurance was
given before patients had expressed any concerns, and therefore
might be expected to be problematic.
Conclusions and implications for clinical practice
This study is observational, so limited conclusions should be
drawn for clinical practice. However, the prevalence of health
anxiety observed suggests that this may be a problem after cancer.
Reassurance was not able to enduringly reduce anxiety, particu-
larly for the most anxious patients, where some particular forms of
reassurance may even be counterproductive.
Oncologists may need to use reassurance as a procedure,
balancing risks benefits and patient selection, to manage cancer
patients in remission, and forms of communication that are
effective in health anxiety could provide interventions for those
who do not benefit from reassurance (Price, 2000; Warwick and
Salkovskis, 2001). When patients report high levels of health
anxiety, reassurance may be better avoided, in particular
reassurance before the patients’ concerns are elicited. If this is
not helpful, for some patients, it may be necessary to replace
reassurance with a careful and respectful switch of the patients’
focus from a physical to a psychological basis of some symptoms
and behaviours. Delivered by mental health professionals where
available, with care to avoid blame and by involving patients in
improving their symptoms, this can be constructive and welcome
to patients (Salmon et al, 1999). Future work on this difficult but
increasingly important area for patients and oncologists may need
to focus upon the efficacy and delivery of such interventions for
selected patients.
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